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Tau is a neuronal microtubule associated protein whose main biological functions
are to promote microtubule self-assembly by tubulin and to stabilize those already
formed. Tau also plays an important role as an axonal microtubule protein. Tau is an
amazing protein that plays a key role in cognitive processes, however, deposits of
abnormal forms of tau are associated with several neurodegenerative diseases, including
Alzheimer disease (AD), the most prevalent, and Chronic Traumatic Encephalopathy
(CTE) and Traumatic Brain Injury (TBI), the most recently associated to abnormal tau.
Tau post-translational modifications (PTMs) are responsible for its gain of toxic function.
Alonso et al. (1996) were the first to show that the pathological tau isolated from
AD brains has prion-like properties and can transfer its toxic function to the normal
molecule. Furthermore, we reported that the pathological changes are associated with
tau phosphorylation at Ser199 and 262 and Thr212 and 231. This pathological version
of tau induces subcellular mislocalization in cultured cells and neurons, and translocates
into the nucleus or accumulated in the perinuclear region of cells. We have generated a
transgenic mouse model that expresses pathological human tau (PH-Tau) in neurons at
two different concentrations (4% and 14% of the total endogenous tau). In this model,
PH-Tau causes cognitive decline by at least two different mechanisms: one that involves
the cytoskeleton with axonal disruption (at high concentration), and another in which
the apparent neuronal morphology is not grossly affected, but the synaptic terminals
are altered (at lower concentration). We will discuss the putative involvement of tau in
proteostasis under these conditions. Understanding tau’s biological activity on and off
the microtubules will help shed light to the mechanism of neurodegeneration and of
normal neuronal function.
Keywords: tau, PH-tau, hyperphosphorylation, propagation, microtubules, neurodegeneration
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INTRODUCTION
Tauopathies are a group of dementias that have in common
the formation of intracellular filamentous deposits seeded
by the microtubule-associated protein tau, in abnormally
hyperphosphorylated form(s). These disorders share a common
diseasemechanism and includes Alzheimer disease (AD), fronto-
temporal dementia with Parkinsonism linked to chromosome
17 (FTDP-17), amyotrophic lateral sclerosis, cortical basal
degeneration, dementia pugilistica, Pick’s disease, progressive
supranuclear palsy, tangle-only dementia, Chronic Traumatic
Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Tau
inclusions are common among all of these tauopathies leading
to diverse phenotypic manifestations, brain dysfunction, and
degeneration. These diseases all implicate abnormal tau, with the
absence of other disease-specific abnormalities (except in AD), in
the onset and/or progression of disease.
Microtubule assembly is promoted and stabilized by the
predominantly neuronal protein tau (Weingarten et al., 1975).
In the central nervous system, tau has six isoforms derived from
a single gene by alternative pro-mRNA splicing (Goedert et al.,
1989; Himmler et al., 1989). In the human brain, tau isoforms
range in size from 352 to 441 amino acids, with differences in
the number of tubulin-binding domain repeats (R), three or four
consisting of 31 or 32 amino acids near the C-terminus, or two,
one, or no inserts of 29 amino acids near the N-terminus. Under
normal conditions, tau is a phosphoprotein, in which isoform
expression and degree of phosphorylation are developmentally
regulated. However, in the disease state, tau has been found to
be abnormally hyperphosphorylated and contains significantly
higher phosphate content than the normal tau resulting from
the phosphorylation at new sites on the protein (Kopke et al.,
1993).
Axonal transport is essential to the growth and survival of
a neuron throughout its life. Disruption of microtubules, as are
observed in patients with AD, interrupts axonal transport which
prevents vesicles and organelles from reaching the synapses.
These result in the slow and steady deterioration of the synapses
and retrograde degeneration. Mutations of MAPT, the tau gene,
were discovered in 1998 and co-segregate with the disease in
FTDP-17, providing unequivocal evidence that abnormalities
in tau alone are enough to cause neurodegenerative disease
(Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al.,
1998). We have shown that hyperphosphorylation of tau
can result in inhibition of microtubule assembly and can
disrupt the preassembled microtubules in vitro (Alonso et al.,
1994, 1997, 2001b). Though the majority of evidence thus
far supports the relationship of tau toxicity with disruption
of the microtubule system, emerging evidence suggest that
tau biological functions are not restricted to the cytoskeletal
system: tau is present in the nuclei (Brady et al., 1995;
Greenwood and Johnson, 1995; Frost et al., 2014; Multhaup
et al., 2015; Bukar Maina et al., 2016) though this physiological
function remains elusive; tau self-acetylation activity has been
described but physiological consequences of this modification
remains uncertain (Cohen et al., 2013); tau has also been
shown to be present in the dendrites under pathological
conditions and impair synaptic function (Hoover et al.,
2010). More recently, the idea of tau transmitting the
disease as a prion-like protein is becoming more attractive.
As tau is found in the extracellular space and can be
uptaken by neighbor neurons, this tau-mediated pathway might
represent an attractive model of therapeutical target to halt
neurodegeneration. In this review article, we will discuss the
putative mechanisms of tau-induced neurodegeneration in light
of the current knowledge and our own experience with tau
models.
TAU: PATHOLOGICAL GAIN OF FUNCTION
Tau Isoforms and Post-translational
Modifications
The gene for tau, MAPT, is located on chromosome 17q21.1.
It is a single copy gene which undergoes alternative splicing to
generate six isoforms found in the human brain (as reviewed in
Andreadis, 2005). The number of N-terminal inserts can vary
(0N, 1N, or 2N) as well as the number of C-terminal repeats
(3R or 4R). These repeats are located in the microtubule binding
domain (MTBD), which can lead to differential polymerization
rates when mixed with tubulin. When analyzed in microtubule
polymerization reactions, recombinant proteins representing
each of these six tau isoforms and the 3R proteins had slower
rates of polymerization than 4R proteins independently of the
N-terminal composition (Goedert and Jakes, 1990). The 4R
and 3R isoforms of tau can be found in an approximately
1:1 ratio in normal adult brains with the 1N form at the
highest level (50%), 0N (40%) and 2N (10%; Higuchi et al.,
2002). Each of the six isoforms have been found in the brains
of AD and other tauopathies (including Downs Syndrome,
amyotrophic lateral sclerosis, Niemann-Pick disease Type C and
some FTDP-17 mutations) at similar ratios as normal brains
(Higuchi et al., 2002; Connell et al., 2005). Other tauopathies,
including cortical basil degeneration, progressive supranuclear
palsy, and other FTDP-17 mutations, appear to express more
4R proteins than 3R proteins at both the mRNA and protein
levels (Higuchi et al., 2002; Connell et al., 2005). Brains from
Pick’s Disease patients show higher 3R levels than 4R in the
sarkosyl insoluble fractions, and this change in the ratio appears
to occur post-transcriptionally (Higuchi et al., 2002; Connell
et al., 2005).
Tau function is modulated by many post-translational
modifications (PTMs) including, but not limited to,
phosphorylation, acetylation, ubiquitination and protein
fragmentation (as reviewed in Beharry et al., 2014; Alonso
et al., 2016). As the review of all of tau PTMs is extremely
challenging due to the large number of modified sites and by
the coexistence of multiple types of modifications, this review
article will focus on how tau changes due to phosphorylation can
affect microtubule stability and regulate not fully elucidated tau
functions. Many of the PTMs lead to changes in the interaction
of tau with other molecules by changing the charge of an amino
acid, or by removing a section of the protein as occurs in
fragmentation. The cleavage of tau by calpains and/or caspases
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can result in molecules that are aggregate-prone which can cause
other full-length tau molecules to aggregate with it (Chung et al.,
2001; Gamblin et al., 2003; Guillozet-Bongaarts et al., 2005;
Mondragón-Rodríguez et al., 2008a,b).
Microtubules and Tau in Alzheimer’s
Disease
In neurons from patients with AD, there is a decrease in
microtubules and a several-fold increase in the concentration of
tau (Kopke et al., 1993). There are three different pools of tau
in the brains of AD patients: AD tau is most similar to normal
tau and is not hyperphosphorylated; AD Phosphorylated tau (AD
P-tau) is soluble hyperphosphorylated tau; and paired helical
filaments (PHFs)-tau is insoluble and hyperphosphorylated. AD
tau in AD brains is decreased by about 60% compared to
tau found in normal brain. AD P-tau, as well as normally
phosphorylated tau, can be isolated from AD brain in solution
(Kopke et al., 1993). Analyzing microtubule-promoting activity
of tau from AD brains, we found that AD tau has normal activity
in in vitro assembly of microtubules assays. Conversely, AD
P-tau did not promote microtubule assembly but this activity was
recovered upon dephosphorylation with alkaline phosphatase
treatment (Alonso et al., 1994; Figure 1). Interestingly, we
found that AD P-tau inhibited the microtubule assembly
promoted by normal tau, MAP1 and MAP2 (Alonso et al.,
1997). Pre-incubation of AD P-tau with normal tau prior to
the addition to tubulin inhibited not only the normal tau-
microtubule–promoting activity but also destroyed microtubules
already present. This was probably due to interactions between
tau and AD P-tau resulting in the sequestering of normal tau
from the tubulin, and suggesting that AD P-tau has prion-like
activity.
AD P-Tau Has Prion-Like Properties
The ability of AD P-tau to bind normal tau was verified using a
solid phase binding assay (Alonso et al., 1996). Quantitation of
this binding was performed using an in vitro assay in solution
and we observed that the binding of AD P-tau to normal tau
was non-saturable (Alonso et al., 1996). Furthermore, analysis
by electron microscopy indicated that the products of these
reactions were bundles of filaments (Alonso et al., 1996). Based
on these results, we hypothesized that the hyperphosphorylation
of tau changed its conformation in such a way that this
change could be transferred to the normal protein, acting as a
prion-like molecule to seed pathological tau self-assembly. The
ability of hyperphosphorylated tau to bind normal tau was also
observed in yeast, a less complex cellular model (Vandebroek
et al., 2005). Expression in yeast of the human four-repeat
and three-repeat isoforms demonstrated that these isoforms
became phosphorylated at pathological sites and assumed a
pathological conformation resulting in aggregate formation. The
phosphorylation was modulated by yeast kinases Mds1 and
Pho85, orthologs of GSK-3β and cdk5. The Van Leuven group
observed many biochemical characteristics similar to those we
had already observed with human tau including a positive
correlation between tau aggregation and phosphorylation; slower
mobility in SDS-PAGE with increased phosphorylation; increase
in the formation of filaments with isolated hyperphosphorylated
tau, and induction of nucleation, or seeding, of normal-non-
P-tau assembly by this hyperphosphorylated tau (Vandebroek
et al., 2005). The prion-like properties of hyperphosphorylated
tau are due to its biochemical stability, which promotes the
aggregation of tau, and are consistent with our observations using
hyperphosphorylated tau isolated from Alzheimer brain (Alonso
et al., 1996). The conformational change transfer by AD P-tau to
normal tau is similar to a property of a prion protein. We were
the first to link hyperphosphorylation of tau to these nucleation
properties of tau (Alonso et al., 1994, 1997, 2001a).
Hyperphosphorylation Induces Prion-Like
Tau Self-Assembly
In AD progression, tau becomes hyperphosphorylated prior
to the appearance of neurofibrillary tangles (Bancher et al.,
1989). Hyperphosphorylated tau shows a 2-3-fold increase
in the number of moles of phosphate per mole of protein
FIGURE 1 | Microtubule disruption can be caused by hyperphosphorylation of tau. (A) Electron micrographs showing the products of microtubule assembly. The
microtubules were negatively stained with phosphotungstic acid. Rat brain tubulin was placed in an in vitro reaction in the presence of (a) control acid-soluble tau,
(b) Alzheimer disease (AD) acid-soluble tau, (c) AD Phosphorylated tau (AD P-tau) and (d) AD P-tau after dephosphorylation. Very few microtubules were observed in
the presence of AD P-tau and dephosphorylation appears to slightly rescue microtubule disruption (Alonso et al., 1994). (B) Cartoon model of microtubule disruption
due to P-tau sequestration of normal tau away from the tubulin resulting in instability and loss of cytoskeletal structure. Image reproduced as authorized by the
editors of Alonso et al. (2016).
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(Kopke et al., 1993) which results from the appearance of new
phosphorylated sites. The increase in phosphorylation can lead
to neuronal degeneration triggered by tau self-assembly into
tangles composed of PHFs and straight filaments (SFs). In
in vitro assays at varying pHs, AD P-tau self-assembled into
tangles of PHFs mixed with SFs (Alonso et al., 2001b). The
PHFs generated were ∼20 nm wide which narrowed to ∼10 nm
at approximately every 80 nm similar to those of AD PHFs.
Within the PHFs, protofilaments (4 nm) and SFs (∼15 nm) were
observed, also similar to those found in AD. Dephosphorylation
of AD P-tau inhibited the self-assembly of tau (Alonso et al.,
1994), suggesting that hyperphosphorylation was required for
filament formation.
Tau intermolecular association leading to self-assembly
appears to occur through the MTBD, whereas the flanking
regions can inhibit these interactions (von Bergen et al., 2000;
Pérez et al., 2001; Alonso et al., 2004). These tau regions have
concentrated positively charged residues, and we postulate that
these patches might be responsible for the inhibition of tau self-
assembly. Supporting this idea, when two N-terminal inserts of
tau, which are highly negative, are present, tau self-assembly is
induced (Alonso et al., 2001b). Phosphorylation of tau, which
introduces negative charges in these regions, results in tau
molecules that acquire the ability to bind normal tau. Tau-tau
interactions begin to form when there are∼4 moles of phosphate
per mole of protein, polymerization of tau leading to fibril
formation begins when there are ∼10 moles of phosphate per
mole of protein (Alonso et al., 2001b, 2004). From these results,
we understand that there are at least two different conformational
states of tau induced by differential phosphorylation. Similar
results are observed by the oxidation of tau by carbonyl
addition to Lys residues, which changes positively charged
residues to negatively charged ones under oxidative-stress
conditions (Santa-María et al., 2005). Consistent with this model,
tau molecules modified by truncation, which eliminates the
positive fragment, can also induce tau self-assembly (Zhou
et al., 2018). In this context, when polyanions are used to
induce aggregation, such as RNA, polyGlu, or heparin, it
would not be surprising that certain phosphorylation sites
appeared to be inhibitory of tau aggregation (Schneider et al.,
1999).
To further understand these structural characteristics of
tau, six isoforms of tau were expressed heterologously,
phosphorylated by treatment with normal brain extract which
contains the kinases and we followed their ability to bind
normal tau and to inhibit microtubule-promoting activity
(Alonso et al., 2001a,b). Proteins treated with rat brain extract
became hyperphosphorylated, ∼12 moles phosphate per mole
of protein (P-tau), which is similar in phospho-level to AD
P-tau. These hyperphosphorylated recombinant proteins were
able to self-assemble into tangles of PHFs/SFs (Alonso et al.,
2001a,b) and inhibit microtubule assembly activity (Alonso
et al., 2001b). Interestingly, the presence of FTDP-17 mutations
on tau also induced conformational changes (Jicha et al.,
1999), decreased the formation of microtubules (Bunker et al.,
2006), and/or increased the ability of tau to self-assemble
(Goedert et al., 1999). To analyze why these mutations may
alter tau activity in a similar manner as phosphorylation,
we generated recombinant tau proteins containing FTDP-17
mutations (R406W, P301L, V337M, or G272V) and incubated
in brain extract as above (Alonso et al., 2004). The results
showed that the presence of these mutations increased the rate
and extent of phosphorylation (∼16–18 moles of phosphate
per mole of protein), suggesting that the mutations induced
the conformational changes described above (Alonso et al.,
2004). These results indicate that the mutated tau molecules
are better substrates for kinases than wild-type tau. This
effect was observed by another group that reported higher
phosphorylation at Ser202 in FTDP-17 mutant tau (Han et al.,
2009). Furthermore, these tau mutants showed filament at lower
mole amounts of phosphate per mole of protein (Alonso et al.,
2004).
Together, our studies indicate that hyperphosphorylation
confers upon tau a toxic property, due to its ability to bind
normal tau and MAPs. However, we have previously shown that
tau filaments do not inhibit microtubule assembly and do not
bind other MAPs potentially due to the neutralization of the
tau peptide involved in tau self-assembly (Ganguly et al., 2015)
by intermolecular interactions (Alonso et al., 2006). Consistent
with this, morphometric study of brain biopsy specimen shows
that the decrease in microtubule density in AD patients was
unrelated to PHF accumulation (Cash et al., 2003). In aged
tau transgenic mice from Takashima’s group, synapse loss
was found in the same brain region as hyperphosphorylated
tau (Kimura et al., 2007). Based on these findings, we
hypothesize that once tau becomes hyperphosphorylated it
can bind normal MAPs and disrupt microtubules, resulting
in the interruption of axoplasmic transport and in synaptic
degeneration. However, upon tau self-assembly, there will be
no contact region for normal MAPs thereby no disruption of
the microtubule network and axonal transport. This model is
in agreement with the results of the European Tau meeting
held last year that has determined that in tauopathies, tau
in aggregates is always hyperphosphorylated (Mudher et al.,
2017).
What Is Hyperphosphorylated Tau? How
Can We Study the Gain of Toxic Function?
Though the defect in tau that leads to aggregation
and neurodegeneration is commonly referred to as
hyperphosphorylated tau, its definition is still unclear. The
debate is whether tau toxic effect is due to a general increase
in moles of phosphate per mole of protein regardless as to
where these modifications are or whether there is a need for
phosphorylation at specific sites within a molecule. Long-range
interaction in tau, and other intrinsically disordered proteins
(IDPs), are modulated by intra- and inter-molecular interactions
and by PTMs, such as phosphorylation, acetylation and others
(Bibow et al., 2011). As an IDP, the secondary structure of
tau is not defined, however, tau structural information is
very important in the formation of PHF/SF in AD brains
(Fitzpatrick et al., 2017). This indicates that our observations
on tau self-assembly using the whole molecule hold more
weight than those using different fragments of tau. The regions
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FIGURE 2 | Pathological human tau (PH-Tau) mimics AD P-tau. (A) A
hypothetical scheme of the phosphorylation-induced self-assembly of
wild-type (left) and fronto-temporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) mutated tau proteins (right). Tau self-assembles
mainly through the microtubule binding domain (MTBD)/repeat R2 and R3.
The β-structure of R2 and R3 is depicted at the cartoon on the bottom.
Regions of tau molecule both N-terminal and C-terminal to the repeats are
inhibitory of self-assembly. Hyperphosphorylation of tau neutralizes these
basic inhibitory domains, enabling tau-tau interaction. The C-terminal region
beyond Pro397 (398–441) is a highly acidic segment masks the repeats.
Phosphorylation of tau at Ser396 and/or Ser404 opens this segment, allowing
tau-tau interaction through the repeats. FTDP-17 mutations make tau a more
favorable substrate for phosphorylation than the wild-type tau. The mutated
tau proteins achieve the conformation required to self-assemble at a lower
level of incorporated phosphate. Although the FTDP-17 mutant tau proteins
have conformations that are more prone to polymerize, in the absence of
hyperphosphorylation, the highly basic segments and the C-terminus interfere
with polymerization. Phosphorylation sites are indicated by red Ps at Ser/Thr
positions in tau (left panel): 199, 202, 205, 212, 231, 235, 262, 396, 404 and
422; and in FTDP-17 mutant tau (right panel): 199, 212, 231, 262 and 396,
respectively. Image taken from Alonso et al. (2004). The Tau cartoon at the
bottom indicates the pseudophosphorylated version of tau that is used in our
studies, PH-Tau (Di et al., 2016). (B) AD P-tau inhibits regeneration of
microtubules. To induce microtubule assembly 3T3 cells expressing AD P-tau
were incubated with 15% fresh rat brain cytosol in buffer containing 1 mM
GTP for 1 h at 37◦C. Cells were processed for immunofluorescence staining
by using DM1-A Ab against tubulin (green) and 134d rabbit polyclonal Ab
(Continued)
FIGURE 2 | Continued
against tau (red). AD P-tau, but not normal tau, inhibited microtubule assembly
(Alonso et al., 2006). (C) PH-Tau, as AD P-tau, inhibits microtubule assembly
when expressed in cells. CHO cells were transfected with either tau, PH-Tau
on the normal tau background (PH-Tau(n)), or PH-Tau on the R406W
background. After 48 h, the cells were permeabilized with 0.1% Nonidet P-40
before fixing and then processed for immunocytochemistry as described in
(B). Merge is shown in yellow. Bar, 25 µm (Alonso et al., 2010). This research
was originally published by Alonso et al. (2010).
N-terminal to the MTBD are very basic with a pI of more
than nine and are separated from other parts of the protein by
Pro residues which are known to introduce kinks in protein
structure (Figure 2A). The positive charges in this region can
mask the negative charges in the MTBD to limit intermolecular
interactions. At the start of tau polymerization, three residues
in this basic region (Thr212, Thr231 and Ser262) have been
shown to be at least 50% phosphorylated, decreasing the pI
of the region (Alonso et al., 2004). On the C-terminal side of
the MTBD, there is a second basic region and phosphorylation
of Ser396 and/or Ser404 may also change the pI, increasing
the potential for intermolecular interactions leading to tau
self-assembly.
Cells treated with AD P-tau showed decreased microtubule
stability (Alonso et al., 2006; Figure 2B). Based on our
knowledge of phosphorylation events in AD brains, we used
phosphomimetics, with and without the FTDP-17 mutation
R406W, to determine whether hyperphosphorylation was
site-specific. Residues that were determined to have about
five moles of phosphate incorporated per mole of protein
when self-assembly occurred were changed to Glu to mimic
the negative charge of phosphorylation or to Ala as a
non-phosphorylatable control. During the initial analysis, nine
sites were found to fit the criteria described above Ser199,
Ser202, Ser205, Thr212, Thr231, Ser235, Ser262, Ser396 and
Ser404. Vectors were generated by site-directed mutagenesis and
then transfected into mammalian cells. Tau proteins containing
the Ala mutations expressed in cell lines acted similarly to
wild-type tau. Conversely, for most of the Glu mutations some
tau dissociation from tubulin was observed, but none exhibited
completemicrotubule disruption (Alonso et al., 2010). Therefore,
single phosphorylation events did not appear to change the
charge of the molecule enough to convert tau into an AD
P-tau like toxic molecule. To try to mimic the toxic nature
of tau, double and triple mutant proteins were expressed in
cells, and the triple combination of T212E/S235E/S262E was
observed to bind weakly to microtubules with a concomitant
decrease in tubulin staining. Furthermore, the triple mutant
protein aggregated in the cytoplasm and nuclear space and
sequestered normal tau similarly to AD P-tau in vitro (Alonso
et al., 2010; Figure 2C compared to Figure 2B). A fourth
residue, Ser199, was found to be highly phosphorylated in the
pseudophosphorylated tau compared to wild-type, suggesting
that phosphorylation at this fourth site was able to convert tau
into a molecule that had gained toxic function. This toxicity was
enhanced by the FTDP-17mutation R406W (Figure 2C). For our
future work, we have focused on a molecule called Pathological
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Human tau (PH-Tau) containing the phosphomimetics of tau at
these four sites (S199, T212, T231 and S262) with the R406W
mutation.
Models Used to Study the Role of Tau in
AD and Other Neurodegenerative
Disorders
Human tau has been overexpressed in many mouse models
which have been shown to reproduce the cognitive impairment
found in AD (Berger et al., 2007; Eckermann et al., 2007;
Lasagna-Reeves et al., 2011; Roberson et al., 2011; Sydow et al.,
2011; Webster et al., 2014) and neuronal death1. The level
of heterologous tau expression in many of these models is
very high compared to levels of endogenous tau which could
lead to mechanistic differences in the analysis of the neurons.
Furthermore, the analysis gets more complicated since tau has
six isoforms, many of these models express variations of human
tau, with or without mouse tau, and with or without FTDP-17
mutations (Lewis et al., 2000, 2001; Tanemura et al., 2001, 2002;
Tatebayashi et al., 2002; Santacruz et al., 2005; Schindowski et al.,
2006; Yoshiyama et al., 2007; Hundelt et al., 2011; Flunkert et al.,
2013). Neurodegeneration is observed in most of these models,
but these mice also have phenotypes not commonly found in
AD, i.e., motor deficiencies due to tau accumulation in the
spinal cord (Lewis et al., 2000; Yoshiyama et al., 2007). Many
groups have switched to the TetOff system to better regulate
tau expression levels and localization. This system utilizes the
Calmodulin Cam kinase II promoter which leads to expression
in the neurons and can be regulated using doxycycline in the diet
(Tatebayashi et al., 2002; Hundelt et al., 2011). Tau expressed
in most of these model systems become phosphorylated at
common Ser/Thr residues that can be linked to pathogenic
phosphorylation sites found in AD as compiled by the Hanger
group2.
A top priority in the research of neurodegenerative disease
is the development of therapeutics. The mouse models that are
generated to express tau phosphomimetics may be a useful tool
in developing and analyzing new treatments for dementia related
to the hyperphosphorylation of tau. However, as described
above, one must be careful to use pseudophosphorylation
patterns that induce similar conformational changes in tau to
those observed in AD P-tau. For example, a mouse model of
hyperphosphorylation which studied a tau molecule containing
10 different pseudophosphorylated residues was generated
with no cognitive impairment or neurodegeneration observed
(Hundelt et al., 2011). Conversely, our studies, including cell
and neuronal culture, Drosophila, and a mouse model, which
target four specific sites (S199, T212, T231 and S262) on tau
resulted in cell death in culture and neurodegeneration and
learning deficiencies in Drosophila and mice (Alonso et al., 2010;
Beharry et al., 2013; Di et al., 2016). Furthermore, we showed
that the toxic effect was stronger when the sites chosen for
pseudophosphorylation were paired with the FTDP-17 mutation
1Alzforum.Org
2https://docs.google.com/spreadsheets/d/1hGYs1ZcupmTnbB7n6qs1r_WV
TXHt1O7NBLyKBN7EOUQ/edit#gid=0
R406W (Alonso et al., 2010; Beharry et al., 2013). In our mouse
model that uses the TetOff system, we found that PH-Tau was
expressed in the forebrain of the mouse and resulted in the
formation of aggregates, synaptic disruption, neurodegeneration,
astrocytosis and cognitive decline (Di et al., 2016; Figure 3).
In this model, PH-tau expression is regulated by the addition
(suppressed) or removal (induced) of doxycycline to/from the
food and/or water of these animals. When expression was
induced, levels of PH-Tau increased up to 14% of total tau protein
(i.e., 14 molecules of PH-Tau per 100 molecules of murine tau)
and aggregates were detected. When expression was suppressed,
there were baseline levels of PH-Tau observed. At this low level,
PH-Tau was detected biochemically as oligomers and triggered
early cognitive deficits (Figure 3A), and loss of synapses in the
hippocampus as determined by decreases in synaptic protein
levels and quantitation of electron micrographs (Figures 3B,C).
While PH-Tau was barely detectable by immunohistochemistry
in tissue sections from these animals, some PH-Tau was
observable and appeared to have translocated in the nucleus.
Dramatic neuronal loss was not observed in those animals
(Figure 3D), but the synaptic changes suggest that at low
levels the effect of abnormal tau expression might not be
related to changes in the cytoskeleton but to its presence in
the nucleus and regulation of protein expression. Interestingly,
when PH-Tau expression was induced, cognitive decline was
somewhat rescued (Figure 3A), the oligomeric forms of PH-Tau
decreased but the sarkosyl-insoluble tau increased, and the
decrease of synaptic proteins and synaptic terminals appeared
to be reversed (Figures 3B,C). We can speculate that at
higher levels, PH-Tau begins to seed a larger amount of self-
aggregation as observed by the formation of sarkosyl-insoluble
tau and that this may prevent the toxic protein from entering
the nucleus. In fact, tau localization was observed in the
perinuclear region of the neurons compared to the nuclear
localization in the low expressing brains (data not shown).
Neuronal death increased in both the CA1 and CA3 regions of
the hippocampus from the mice in which PH-Tau expression
was induced (Figure 3D). By increasing the expression of
PH-Tau, which resulted in the increase of its aggregation
propensity into sarkosyl insoluble aggregates, the impairment
of cytoskeletal function begins potentially by the sequestering
of normal tau from the microtubules, thereby increasing their
instability (Di et al., 2016). These results are comparable to
the effects of hyperphosphorylated tau in the brains of AD
patients. Based on these different observations, it appears that
the specific sites that are phosphorylated or modified, rather
than the number of sites, may be an important factor in tau
toxicity.
CONCLUSIONS AND FUTURE
DIRECTIONS
It is apparent that tau hyperphosphorylation is an early event
in the disease progression for AD and other tauopathies,
though there are other modifications that can also affect the
protein. From all that we have learnt through our research
and those of our fellow scientists, we can propose that these
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FIGURE 3 | Characterization of PH-Tau mouse model. (A) Bigenic mice (12-month old) were tested for behavior deficits in the Novel Object Recognition task.
Significant decreases in spatial memory and memory storage were observed. (B) PH-Taulow mice shows significant loss of synapses, decreased post-synaptic
density and enlarged pre-synaptic portion. Decrease in the length of the post-synaptic density was observed in both PH-Taulow and PH-Tauhigh mice. Synapses in
CA1 stratum radiatum area are shown in the magnified images of square boxes. Quantitation of the number of synapses in the CA1 stratum radiatum area is shown
in the bottom of the figure. (C) Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, PSD95 and β-III-tubulin were
measured. Loss of synaptic proteins was observed in PH-Taulow mice. (D) Coronal slices of hippocampus stained with antibody NeuN recognizing nucleus of
neurons (Left). Scale bar = 50 µm. Counts of the NeuN positive cells in both the CA1 and CA3 regions. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; right; Di et al. (2016).
modifications of tau can modulate different events at the
cellular levels with important consequences for its physiology
(Figure 4), including converting the protein from a microtubule
stabilizer to a microtubule disrupter inducing a pathological
state. Changes in the cytoskeleton might not be the only
effect of these mdifications on tau. In our lab, tau has
been observed to translocate into the cell nucleus (Alonso
et al., 2010; Di et al., 2016). Though tau has been shown
to interact with nuclear DNA, hyperphosphorylation can alter
this interaction with potential changes at the chromatin and
transcriptional level, thereby changing its physiological role
(Hua and He, 2003; Wei et al., 2008; Padmaraju et al., 2010;
Sultan et al., 2011; Qi et al., 2015). Our preliminary studies
suggest that tau in the nucleus may also be involved in the
regulation of mRNA stability, which would result in potential
changes at the transcriptome and proteome by regulating
gene expression, thus affecting cellular function during the
progression of neurodegeneration. We have recently found that
tau can associate with factors involved in mRNA 3′ processing,
such as the tumor suppressor p53 (Devany et al., 2013) and
PARN deadenylase (Cevher et al., 2010), and that the formation
of tau/p53/PARN complex(es) in the nucleus can regulate
mRNA 3′ end processing. Interestingly, these interactions are
regulated by tau phosphorylation state (Baquero et al., 2015).
These changes might happen at very early stages of disease
progression.
We have described above how hyperphosphorylated tau can
destabilize the microtubules but it can also interact with actin
causing a destabilization of these microfilaments (Elie et al.,
2015). Disruption of the microfilaments can lead to zeiosis of
the cell membrane due to their important role in membrane
stability. We have observed that as membrane pinches off
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 October 2018 | Volume 12 | Article 338
Alonso et al. Hyperphosphorylated Tau: Mechanism of Neurodegeneration
FIGURE 4 | Proposed mechanisms of neurodegeneration. (A) Hyperphosphorylation of tau affects multiple cellular processes. PH-tau aggregates are formed when
the balance between kinases and phosphorylases is disrupted. The aggregates can begin to disrupt the stability of the microtubules. This toxic molecule has also
been shown to translocate into the nucleus, cause intracellular degeneration, protein aggregation and vacuole formation. The presence of tau in the nucleus might be
involved in alterations of protein expression. Disruption of the actin cytoskeleton can lead to membrane zeiosis and tau can be released from the cells, potentially
propagating the disease to neighboring cells. Image reproduced from Alonso et al. (2016). Permissions were obtained through RightsLink License Number:
4358781157689. (B) Left panel: low level of PH-tau expression results in translocation to the nucleus, synaptic dysfunction and mitochondrial disruption. The
presence of tau in the nucleus might be involved in alterations of protein expression. Right panel: high levels of PH-Tau expression results in protein aggregation,
microtubule disruption and loss of synapses. Loss of cytoskeletal stability leads to neurodegeneration (Alonso et al., 2017). Permission granted to reproduce figure
from Alonso et al. (2017).
during exocytosis, there is a release of hyperphosphorylated
tau within the vesicles. These tau-containing vesicles have
the potential to be taken up through endocytosis, or some
other mechanism, into neighboring cells. We were the first
to show that hyperphosphorylated tau sequesters healthy tau
protein causing it to take on the toxic function of the
pathological protein (Alonso et al., 1996). These findings support
the prion-like nature of hyperphosphorylated tau which can
spread its pathology to surrounding cells by moving from
cell to cell and sequestering healthy tau which causes a
disruption of all cytoskeleton components, destabilization of the
organelles, disruption of protein synthesis and eventually zeiosis
induction.
Zeiosis of the cell membrane is expected to release
hyperphosphorylated tau-containing membrane vesicles.
While we do not know the physiological role, if any, of
tau in the extracellular space, it is possible that soluble
hyperphosphorylated tau is uptaken by non-affected neurons
through its interaction with the muscarinic receptor triggering
the signal transduction pathway (Gómez-Ramos et al.,
2006, 2008). Supporting this model, our preliminary results
indicate that the muscarinic receptors are involved in tau’s
uptake (Morozova et al., 2017). It is also possible that
hyperphosphorylated tau-containing membrane vesicles are
taken up by endocytosis by surrounding cells. This model of tau
transmission might be therefore addressed with immunotherapy
(Iqbal et al., 2018).
Different scenarios can be considered where the levels of
hyperphosphorylated tau begin increasing to toxic levels due
to kinase overactivity, phosphatase deficiency, failure in the
clearance system or a combination of these and others. Early
in disease progression, modified tau may translocate into the
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nucleus, move to synapses, or interfere with mitochondrial
homeostasis (Figure 4B, left). Any or all of these physiological
changes could lead to cognitive impairment without significant
structural changes, as observed in our mouse model under
conditions of low PH-Tau expression (Di et al., 2016). As
disease progression continues, the levels of pathological tau
tend to increase in the neurons to levels that begin to
disrupt microtubule stability and other cytoskeletal components
which can trigger retrograde neurodegeneration (Figure 4B,
right). Despite these different mechanisms, it appears that
therapeutics to reduce the levels of hyperphosphorylated tau
as well as therapeutics aimed at preventing cytoskeleton
disruption remain as key targets for tauopathies (Corbo and
Alonso, 2011). The development of combination therapies
that address the multiple physiological changes induced by
hyperphosphorylated tau may help to unravel the process
of neurodegeneration and reduce the number of patients
affected.
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